The European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) guideline update on the management of dyslipidemia continues to focus largely on how best to manage lipid levels to reduce cardiovascular (CV) risk. Although some things have remained the same, some important new recommendations have been added, based on evidence from several clinical trials published from 2019 onwards.
Autoren
- Mirjam Peter, M.Sc.
Publikation
- HAUSARZT PRAXIS
Related Topics
You May Also Like
- HER2-positive breast cancer
ENPP1 as a biomarker for poor prognosis and early detection of brain metastases
- Update 2025
Hypercholesterolemia
- GPP: from molecular principles to targeted therapy
Therapeutic rationale for targeted IL-36 receptor inhibition
- HFpEF 2025
Precision medicine and phenotypes
- Myelofibrosis
New treatment options for myelofibrosis patients with a high risk of anemia?
- Chronic insomnia in adults: Guideline recommendations
CBT-i as first choice – pharmacotherapy as secondary intervention
- Pulmonary hypertension
PH and lung diseases
- COPD therapy